The most famous pharmaceutical companies in the country. World ranking of pharmaceutical companies

Over the past 12 months, the pharmaceutical market has shown strong growth, which means that the income of drug manufacturers is growing steadily. Pharmaceuticals are traditionally considered one of the most profitable sectors of the economy.

However, entering this market is not at all easy, because large manufacturers invest billions of dollars in drug development, patenting and sales. Today we present rating of the largest pharmaceutical companies, which presents the world's main players in the medicinal industry.

The company was founded in 1863 in Germany. Bayer produces pharmaceuticals for humans and animals, food additives, and agrochemical fertilizers.

9.Merck & Co

The headquarters of this pharmaceutical company is located in New Jersey, USA. Merck & Co. was founded in 1891 as a subsidiary of the German company Merck KGaA. During the war, the division was confiscated by the American government and turned into an independent company.

8. Abbott Laboratories

The American pharmaceutical company was founded in 1888. And in 2010, Abbott Laboratories' turnover exceeded $35 billion. The company employs more than 91 thousand people.

The Swedish-British company was founded in 1999 by merging the Swedish Astra AB with the British Zeneca. AstraZeneca's turnover is about $25 billion. Today the pharmaceutical company employs more than 50 thousand people.

The French pharmaceutical company produces drugs for various diseases, vaccines, oncology drugs, etc. At the same time, Sanofi is an employer of 112 thousand people.

The Swiss company was founded in 1996. Novartis' subsidiary brands include contact lens makers Alcon and Ciba Vision, as well as pharmaceutical company Sandoz.

The British pharmaceutical company has offices in 114 countries. GSK operates 24 research and development laboratories. The company's employees are 99 thousand people.

The Swiss holding is active in the market of innovative drugs. F. Hoffmann-La Roche owns three subsidiaries operating in the field of biotechnology. The holding is an employer of 85 thousand people.

The American company was founded in 1849 by two cousins, immigrants from Germany. The company's turnover today exceeds $51 billion. Pfizer employees are 78 thousand people.

The world's largest pharmaceutical company In addition to medicines and medical supplies, it produces household chemicals, contact lenses, cosmetics and medical equipment. The company's turnover is 471 billion per year. Johnson & Johnson employs 128 thousand people.

Biopharmaceutical industry very dynamic. Big Pharma players in 2016 resorted to a variety of ways to increase income. Some of them relied on innovative drugs, while others were actively developing biosimilars - analogues of drugs of biological origin that had lost their exclusivity. Pharmaceutical companies have worked productively in many areas of medicine, but the development of advanced cellular and gene technologies, for example, in the field of immunological oncology and the treatment of neurodegenerative diseases, seems especially promising. To reorient industry priorities and implement development strategies, companies exchanged assets and expanded product portfolios. In this publication, you will be able to get acquainted with the top five leaders of the global pharmaceutical market in terms of sales income at the end of 2016, as well as the methods that helped companies achieve such great heights.

Not all Big Pharma players saw tangible benefits in 2016 in terms of increased sales revenue. 4 companies from the above five increased their sales income in 2016 compared to 2015 (table), but a significant increase in the indicator is typical only for Pfizer and Roche (8 and 5%, respectively). For Johnson & Johnson and Roche, the total sales revenue for all divisions is shown.

Source: “Top 15 pharma companies by 2016 revenue” report by FierceFarma.

To increase sales revenue, they are actively developing new drugs, looking for opportunities to acquire “successful” assets and ways to intensify the promotion of products on the market. Let's consider what strategic steps the companies from the above top 5 took in 2016.

"JOHNSON & JOHNSON"

The company is known for regularly adding new products to the global pharmaceutical market, while its shareholders can remain calm due to the stability of stock prices. Total sales revenue for all Johnson & Johnson divisions in 2016 was $71.9 billion. USA, and global sales of the company's pharmaceutical division are $33.5 billion. with a 6.5% increase in this indicator compared to 2015.

Blood cancer drug Imbruvica (ibrutinib) had a banner year in 2016, with sales of $1.2 billion, up 86% from 2015. It is a first-in-class Bruton's tyrosine kinase inhibitor. , which Johnson & Johnson released in collaboration with AbbVie. According to EvaluatePharma, the drug will be the third best-selling cancer blockbuster in the world in 2022, with projected sales revenue of $8.29 billion.

Johnson & Johnson certainly entered 2017 in better shape than it did in 2016. During that time, it made several important moves. The largest of these was a complex $30 billion deal that began negotiations in 2016 and ended in January 2017. Johnson & Johnson acquired Swiss biotech company Actelion Pharmaceutical Ltd. and for 280 dollars. per share received a Swiss biotech portfolio of promising drugs, including Opsumit (macitentan) and Uptravi (selexipag) - drugs for the treatment of pulmonary arterial hypertension. Once the deal is completed, the company expects to see rapid earnings growth from sales of these drugs, which generated more than $1 billion in revenue in 2016.

In the stock market, Johnson & Johnson continues to maintain high profitability. In 2016, the value of its shares increased by 12% compared to 2015. In terms of share price growth, the company ranked between GlaxoSmithKline (14%) and Merck & Co (11%). This provision is seen as a "safe harbor" in a volatile pharmaceutical market.

Johnson & Johnson confidently promotes new products to the market thanks to the professional work of marketing specialists. Johnson & Johnson CEO Alex Gorsky said that in 2017, professional marketing will help achieve a 4-5% increase in profits compared to 2016. According to company experts, sales income in 2017 will be 74.1–74.8 billion dollars, and adjusted profit - 6.93–7.08 dollars. per share.

"PFIZER"

In 2016, an important event was to take place in the global pharmaceutical market - the merger of Pfizer Inc. and Allergan, but the deal was cancelled. Despite this, Pfizer reported higher profits in 2016 and is expanding its distribution footprint to maintain that growth.

Pfizer is strengthening its position in the global market: in 2016, its sales in monetary terms increased by 5% ($2.2 billion) compared to 2015 and reached $48.1 billion. In the United States, the increase in this indicator was more significant, sales income increased by 21% ($4.7 billion) over the specified period. A number of products played an important role in this: the breast cancer drug Ibrance (palbociclib), the antiepileptic drug Lyrica (pregabalin), the anticoagulant Eliquis (apixaban), the arthritis drug Xeljanz (tofacitinib) and the nicotine addiction drug Chantix (varenicline). . In total, during the period under review, the volume of their sales in monetary terms increased by more than $2.8 billion.

Palbociclib saw sales revenue soar from $723 million. in 2015 to $2.14 billion. in 2016. The Company expects the product to become more profitable in the future as physicians prescribe it to a wider range of patients.

Meanwhile, apixaban has created excitement in the market for a new generation of anticoagulants. After a tepid start, Pfizer and its partner Bristol-Myers Squibb have invested heavily in marketing the drug, and the drug is now catching up to Johnson and Johnson's Xarelto (rivaroxaban) in terms of marketing investment.

In 2016, Pfizer was able to close several important deals that it believes will help increase revenue. In August, it acquired the company Medivation, which was a tasty morsel for many Big Pharma players. By entering into a purchase agreement, Pfizer acquired the rights to the prostate cancer drug Xtandi (enzalutamide).

Prior to this, Pfizer acquired Anacor Pharmaceuticals and secured the rights to the potential blockbuster eczema treatment Eucrisa (crisaborole), which was approved by US regulators in December 2016.

The company is not going to stop there. It plans to continue making acquisitions that will drive earnings growth, said Frank D'Amelio, the company's chief financial officer. And if the U.S. considers tax reforms affecting the flow of funds from abroad, Pfizer will have plenty of room to make such purchases.

"ROCHE"

Roche derives consistent revenue from a successful portfolio of oncology blockbusters such as Avastin (bevacizumab), Herceptin (trastuzumab) and Rituxan (rituximab). Compared to 2015, the Swiss company's global sales revenue increased by 4% in 2016, and its net profit increased by 7% ($9.8 billion). The company's analysts calculated that sales growth will remain at this level in 2017. Chief Executive Officer Severin Schwan expects innovation to be the pharmaceutical manufacturer's main driving force in the future.

Roche's new products, such as Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine), are intended to treat aggressive metastatic breast cancer. The pharmaceutical company tested their combinations with time-tested drugs. If successful, this approach could stimulate sales of both older and newer drugs.

The combination of Herceptin and Perjeta increased revenue from sales of these products. In 2016, sales of the first drug in monetary terms increased by 4% (to $6.7 billion) compared to 2015, and the second by 26% (to $1.8 billion), which allowed it take 4th place in the ranking of Roche products in terms of sales income for 2016. For the drug Kadcyla, this figure increased by 7% (to $821 million) for the specified period.

Tecentriq (atezolizumab) from Roche is the company's first immuno-oncology product. The drug's revenue is expected to skyrocket in the near future as Tecentriq received U.S. Food and Drug Administration approval in October 2016 for the treatment of non-small cell lung cancer. The drug was previously approved for the treatment of urothelial carcinoma, the most common bladder cancer.

Roche launched four new drugs and nine diagnostic tests in 2016, and is expecting some key regulatory approvals in 2017, including the approval of Ocrevus (ocrelizumab), a potential multiple sclerosis drug that could be its biggest launch yet in 2017

"NOVARTIS"

In a massive $25 billion asset swap, Novartis sold its veterinary division (Novartis Animal Health) to Eli Lilly and its vaccine business to GlaxoSmithKline in exchange for some of the British drugmaker's oncology assets . The deals come as the Swiss company focuses primarily on cancer drugs. Novartis plays a critical role in the rapid development of the immunological oncology field. The company is focused on the next wave of drugs in this promising area and has a portfolio of drug candidates in development.

In the fall, Novartis achieved priority review for the LEE011 molecule. This substance is also known as ribociclib and could compete with Ibrance, Pfizer's famous oncology product. The analytical company EvaluatePharma considers ribociclib as a promising launch of the year, and its projected sales revenue in 2022 is estimated at $1.6 billion.

Novartis CEO Joe Jimenez says biosimilars will be a key driver of the company's revenue growth in the future. Approval is expected in August 2017 for a biosimilar to Amgen's tumor necrosis factor inhibitor Enbrel (etanercep). Novartis plans to launch biosimilars to Humira (adalimumab, AbbVie), Rituxan (rituximab, Biogen) and Remicade (infliximab, Johnson & Johnson) in the near future.

D. Jimenez also expects the company's revenue to increase thanks to new products such as Cosentyx (secukinamab), a drug for the treatment of psoriasis. It achieved blockbuster status in 2016, achieving sales of $1.1 billion.

Novartis is interested in conducting mergers and acquisitions worth up to $5 billion. and plans to actively continue activities in this area.

"MERCK & CO"

In 2016, Merkс & Co increased its revenues on the global market by 1% compared to 2015 and is optimistic about the future. For her, an important milestone was that in 2016 the drug Keytruda (pembrolizumab) received blockbuster status with sales revenue of $1.4 billion. - this is a big breakthrough compared to income of $566 million. in 2015. The drug competed with Opdivo (nivolumab), a product of Bristol-Myers Squibb.

Merck & Co. has operated during a period of significant volatility and uncertainty, including the current political and regulatory environment in the United States, as CEO Ken Frazier told investors and company analysts at a conference in late 2016. However, he believes Big Pharma players will weather these uncertainties through their broad and balanced product offerings.

Merkс & Co became one of the leading pharmaceutical companies in terms of share price growth in 2016, second only to GlaxoSmithKline and Johnson & Johnson.

The company was able to increase worldwide sales revenue for Januvia (sitagliptin) in 2016 compared to 2015, an important win as intense competition among diabetes drugs has hurt some competitors' profits. During this period, Januvia's sales volume in monetary terms increased by 2%, reaching $6.1 billion.

The human papillomavirus vaccine Gardasil has become another successful product from Merkc & Co. The franchise led to a double increase in income from vaccine sales: in 2016, the figure increased to $2.17 billion.

Entering 2017, the company believes its profitability is improving, which will lead to higher net earnings per share. In 2016 in the USA this figure was 2.04 dollars, and its range in 2017 is calculated as 2.47–2.62 dollars.

After the announcement of financial results for 2016, Merkc & Co announced that its drug candidate for HIV therapy - doravirine - showed significant success in phase III clinical trials and, after entering the market, will be able to become a worthy competitor to the company's drug Prezista (darunavir). Johnson & Johnson.

RESULTS

Large ones have significant potential to balance in difficult conditions in the global market thanks to a wide product portfolio. In 2016, Big Pharma players placed bets on both proven and innovative drugs and the development of biosimilars, invested in the development of products in new areas of medicine, for example, immunological oncology, exchanged assets and replenished product portfolios in order to increase revenues from sales in the future.

Bayer is an international company with expertise in the natural sciences: health and agriculture. The company includes about 302 representative companies in 75 countries. The company's products and services are aimed at benefiting people and improving the quality of life. The company's activities are based on the principles of sustainable development, economic stability and social responsibility.

The company was founded in 1863 in Barmen (now a district of Wuppertal) by Friedrich Bayer and Johann Friedrich Weskott as the general partnership of Friedr. Bayer et comp. The company was created for the purpose of producing and selling synthetic dyes.

Today, the company's business operations are carried out through three divisions: Pharmaceuticals develops and manufactures prescription drugs and healthcare products, Consumer Health offers over-the-counter products, and Crop Science works in the field of crop protection for quality food companies, including animal health.

In 2016, the group's global workforce amounted to 115,200 people and its sales volume amounted to 4.7 billion euros. Capital expenditures in 2016 amounted to 2.6 billion euros, and research and development expenses amounted to 4.7 billion euros.

Bayer has been doing business in Ukraine since 1992. A team of more than 450 professionals works to present their knowledge and innovations in new products of the Ukrainian industry.

British pharmaceutical company, one of the largest in the world. Headquarters are in Brentford, a suburb of London. The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.

The main production facilities are concentrated in the UK, Spain, Ireland, USA and Singapore. The main sales come from drugs in therapeutic areas: respiratory diseases, oncology, HIV/AIDS, diabetes, mental disorders, prevention of infectious diseases (vaccines for various age groups).

Johnson & Johnson is the world's largest manufacturer of human health products, pharmaceuticals and medical devices. In Russia and the CIS countries, Johnson & Johnson products have been represented in three areas since 1992: consumer products, products for hospitals, and pharmaceutical products.

The pharmaceutical division is represented by the Janssen group of companies, whose research includes oncology (including multiple myeloma and prostate cancer), immunology (psoriasis), psychiatry (schizophrenia, Alzheimer's disease), infectious diseases (HIV/AIDS, hepatitis C and tuberculosis) , as well as cardiovascular diseases and metabolic disorders (diabetes).

Today, MSD is one of the world's leading healthcare providers, providing consumers with medicines, vaccines, biologic therapies, general medical products and veterinary products.

The company does business in more than 140 countries, introducing innovative solutions to maintain and restore health. MSD's drug portfolio and core research focuses on treating and preventing diseases that pose major threats to public health: infectious diseases, cardiovascular diseases, diabetes, women's health and respiratory diseases.

Novartis is a transnational pharmaceutical corporation, currently consisting of six business divisions: Pharma (innovative prescription drugs), Alcon (full range of vision care products), Sandoz (high-quality generics and biosimilars), OTC (over-the-counter products), Vaccines and Diagnostics (vaccines and test systems), Animal Health (medicines for animals).

The main areas of research and development of Novartis (Novartis) are oncology, cardiovascular diseases, ophthalmology, neurology, and biological drugs.

The company is also developing innovative areas such as immuno-oncology, aging prevention, regenerative medicine and infectious diseases.

The headquarters is located in Basel, Switzerland. The company employs approximately 120,000 employees in more than 140 countries.

The representative office of Novartis in Ukraine was opened in 1993.

The company was founded in 1896 in Basel, Switzerland, and today has offices in 150 countries and employs more than 80,000 people. As one of the leading manufacturers of original drugs in the field of oncology, virology and transplantology, the company pays special attention to the issues of combining the effectiveness of its drugs with the convenience and safety of their use.

In addition to the company F. Hoffmann - La Roche, the Roche group includes Genentech, USA and Chugai, Japan. Roche's activities in Ukraine began in 1998 with the establishment of a Representative Office. In 2009, Roche Ukraine LLC was registered.

Sanofi is a diversified pharmaceutical company. Its divisions operate in more than 100 countries around the world. Sanofi's subsidiaries are the following companies: Sanofi Pasteur – production of vaccines; Genzyme is an innovative biotechnology company; Chattem – production of over-the-counter drugs; Merial – production of veterinary drugs; Zentiva – production of generics.

Main areas of work: emerging markets; diabetes; vaccines; health products; innovative products; animal health.

Teva Ukraine LLC is part of TEVA Corporation, a leading international pharmaceutical company specializing in the development, production and marketing of generic and original medicines, as well as active pharmaceutical ingredients.

The company began operating in Ukraine in 1997 and is now one of the top three leaders in the Ukrainian pharmaceutical market. Today about 400 employees work here.

The company's activities in Ukraine are concentrated in the following areas of medicine:

• central nervous system diseases
• mental illness
• diseases of the respiratory system of both viral and bacterial etiology
• oncology
• diseases of the cardiovascular system
• women Health
• bone metabolism disorder
• diseases of the liver and gastrointestinal tract.

AbbVie is a global research and development biopharmaceutical company.

The company's activities are focused on the development of medications with a pronounced clinical effect, benefiting the patient and being cost-effective, especially in those areas where there is the greatest need for them, in particular in the treatment of hepatitis C, chronic kidney disease, neurology, immunology, oncology and women's health.

On December 19 in Moscow, the National Pharmaceutical Rating awarded the best manufacturers of medicines and medicinal cosmetics, as well as the most successful brands.

Selection of nominees built on objective indicators – sales volumes of pharmaceutical products. The rating is based on independent research and analytics by DSM Group.

Results of the “National Pharmaceutical Rating - 2017”:

• The company won in the Rx-manufacturer category, with Pfizer in second place and Pfizer in third.
• The company topped the OTC Manufacturer nomination "OTCPharm", followed by Bayer, and Johnson & Johnson closes the top three.
• In the “OTC-drug” category the first place is taken by "Kagocel", on the second - "Nurofen", on the third - "Ingavirin".
• The brand won the Rx-drug category "Prevenar 13", in second place is Revlimid, in third place is Kaletra.
• In the nomination “Rx-drug on the pharmacy market” the first place is taken by "Concor", on the second – “Actovegin”, on the third – “Xarelto”.
• In the nomination “Dietary Supplement Manufacturer”, the first place, as in the previous year, is taken by the company "Evalar", in second place is PharmaMed, and Solgar Vitamin and Herb closes the top three.
• First place in the category “Brand Dietary Supplements” Solgar, in second place is the brand “Doppelgerts”, in third place is “Vitamishki”.
• In the category "Cosmetics Manufacturer" in first place - L'Oréal, followed by the Zeldis-Pharma company, and Pierre Fabre closes the top three.
• In the “Cosmetics Brand” category – first place – Librederm, in second place is La Roche Posay, in third place is Vichy.
• In the “Toothpaste Brand” category, the leaders were distributed as follows: in first place R.O.C.S., on the second Lacalut, on the third Splat.
• Nomination “Wound care products and first aid. Manufacturer" was headed by the company Paul Hartmann, Johnson & Johnson is in second place, Veropharm is in third place.

“The purpose of the National Pharmaceutical Rating is to evaluate the results of work and identify leaders in terms of sales volume in Russia over the past year, recognize the best in the industry and deservedly reward those who provide the country with quality medicines and value the social component of their activities. This year’s ceremony is distinguished by an important charitable mission: along with summing up the results of the rating, we collected gifts for two orphanages and for the House of Stage Veterans named after. A. Yablochkina. Next week we will organize the transfer of all the gifts, and this will be another small but pleasant occasion in creating a New Year’s mood for everyone,” says the CEO of DSM Group Sergey Shulyak.

The awards ceremony for the nominees of the National Pharmaceutical Rating brought together more than 300 participants and guests, leading show business artists, the media, as well as top managers of pharmaceutical companies and industry associations. The award ceremony was celebrated in the Miх Afreparty hall with the energy of a real rock party, with drive and in a format unusual for official events.

Top 10 pharmaceutical companies in the world 2014

Below is a global ranking of pharmaceutical companies. Modern technologies and scientific developments have allowed these companies to produce high-tech products, thereby receiving tens and even hundreds of millions of dollars in profit per year.
We can claim that the production of these companies in terms of technology and equipment is at the top of world achievements in this field. They use the most modern technology, equipment and the latest scientific developments. The rating is based on annual product sales.

1. Johnson & Johnson

Johnson & Johnson is an American pharmaceutical company, but it also produces consumer products. The company was founded in 1886 and consists of three main production complexes: pharmaceuticals, medical instruments, and diagnostic equipment.
It employs approximately 128,100 people. The company produces a variety of household medicines for first aid. Some of the famous Johnson & Johnson brands include: Band-Aid, Tylenol, Neutrogena. In December 2012, the FDA approved Johnson & Johnson's drug Sirturo. Sirturo is an anti-tuberculosis drug, it is the first new drug to fight the infection. Another new drug is Invokana, which was the first SGLT2 inhibitor approved by the FDA and is aimed at improving the body's absorption of glucose.

Sales: $65,030,000,000

It is a Swiss pharmaceutical company based in Basel, Switzerland. It was created in 1996 by merging Ciba-Geigy with Sandoz. Number of employees: 135,696 people.
In 2003, Novartis began active production of generics through its Sandoz subsidiary. The company's business is divided into six production divisions:
1. Drugs that can be sold without a prescription;
2. Preparations for animals;
3. Vaccines;
4. Diagnostic tools;
5. Generics;
6. Drugs for large orders;
The main drugs produced by Novartis are clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and others.

Sales: $57,920,000,000

3. Pfizer Inc.

Pfizer is an American pharmaceutical company with corporate headquarters in New York City, and R&D headquarters in Connecticut, USA. It was founded in 1849 by cousins ​​Charles Pfizer and Charles Earhart.
The company has 78,000 employees. Pfizer develops medicines and vaccines. The company's products are known in various medical fields, including immunology, oncology, cardiology, diabetology, endocrinology and neurology. Pfizer's products include such well-known drugs as: Lipitor (atorvastatin), Lyrica (pregabalin), Diflucan (fluconazole), Zithromax (azithromycin), Viagra (sildenafil), and Celebrex (celecoxib).

Sales: $52,700,000,000

4.Roche

This is a Swiss healthcare company. It was founded in 1896 by Fritz Hoffmann-La Roche.
At that time, it produced various vitamin preparations and derivatives. Today, the company employs 85,000 people. The company consists of two divisions producing pharmaceutical products and diagnostic products.
The company's headquarters is located in Basel, and its products are manufactured at 26 production sites around the world. Roche is the first company to sell synthetic vitamin C. Its mass production began in 1934, under the Redoxon brand.
Roche is a leader in the production and sale of cancer drugs. The company created the first antidepressant, Iproniazid, by accident while working to synthesize isoniazid, a drug used to combat tuberculosis.
Roche produces diabetes products under its Accu-Chek brand.

Sales: $50,500,000,000